goserelin acetate

P3, N=94, Completed, Eurofarma Laboratorios S.A. | Recruiting --> Completed

For young breast cancer patients with clinical stages of ⅡA~ⅢC, there was no statistical difference in pCR rate and ORR whether or not using goserelin during NAC. However, it is still necessary to expand the sample size and carry out a longer follow-up to evaluate the effect of goserelin on the long-term survival of young patients.

P2, N=50, Not yet recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

P=N/A, N=146, Active, not recruiting, Stanford University | Trial completion date: Dec 2026 --> May 2026

P4, N=200, Recruiting, The First Affiliated Hospital of Guangxi Medical University; The First Affiliated Hospital of Guangxi Medical University

P=N/A, N=10, Not yet recruiting, Alfred Health

P3, N=2050, Recruiting, NRG Oncology | Trial completion date: Apr 2037 --> Nov 2026 | Trial primary completion date: Apr 2032 --> Nov 2026

This real-world analysis indicates that 3-month goserelin 10.8 mg is non-inferior to monthly 3.6 mg among premenopausal women with breast cancer in terms of 12-month rwEFS rate. These findings may support the use of the 3-month goserelin 10.8 mg as an alternative treatment option to monthly goserelin 3.6 mg for this patient population.

P2, N=33, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial primary completion date: Mar 2025 --> Sep 2025

P3, N=1400, Not yet recruiting, Novartis Pharmaceuticals | N=3100 --> 1400

P1, N=181, Active, not recruiting, Genentech, Inc. | Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Jun 2025 --> Jun 2026

P3, N=315, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2024 --> Dec 2025

Overall, our results reveal that GnRHR suppresses the malignant progression of TNBC by upregulating FOS and IFI44L. Goserelin slows down the proliferation of TNBC tumors in vivo through the GnRHR/FOS/IFI44L pathway, which may present a new therapeutic approach for the management of TNBC.

Additionally, diarrhea improved after symptomatic treatment. We believe that the combination of trastuzumab, hormone suppression, and abemaciclib is a practicable and effective treatment for HER2-positive and HR-positive metastatic BC in premenopausal patients who cannot tolerate the first-line chemotherapy.

The findings of this systematic review highlight the benefits of adding goserelin to endocrine therapies for OFS and chemotherapy for OFP in early-stage breast cancer. Additionally, scientific data supporting OFS (including goserelin) in combination with newer agents such as cyclin-dependent kinase 4 and 6 inhibitors and bone-modifying agents are emerging.

P3, N=6, Terminated, Eurofarma Laboratorios S.A. | N=68 --> 6 | Recruiting --> Terminated; Low recruitment rate and number of subjects is less than required after 3 years.

P2, N=192, Not yet recruiting, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

P2, N=310, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Feb 2025 --> Feb 2027 | Trial primary completion date: Feb 2025 --> Feb 2027

Of 26 patients who received goserelin at an AIS, all patients reported the absence of menses with no tolerability concerns. For patients who may want to avoid abdominal administration, injection of goserelin at an AIS appears to be a viable strategy and offers flexibility for OFS management in breast cancer.

P2, N=74, Not yet recruiting, University of Chicago | Initiation date: Jan 2025 --> Jan 2026

P2, N=66, Terminated, Breast Cancer Trials | Recruiting --> Terminated

P3, N=27, Active, not recruiting, ECOG-ACRIN Cancer Research Group | Trial primary completion date: Jun 2025 --> Dec 2025

P3, N=600, Active, not recruiting, Abdenour Nabid | Trial completion date: Dec 2023 --> Dec 2027 | Trial primary completion date: Dec 2023 --> Dec 2026

P1, N=17, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Dec 2024 --> Oct 2025

Moreover, our in-silico analysis identified Goserelin, Paclitaxel, Raloxifene, Exemestane, Epirubicin, Trametinib, Vemurafenib, Pactitaxel, and Sorafenib as potential anticancer agents for curing MPS-based cancer. Interestingly, some sorts of MPs also displayed suppressive effects on cancer cells in some particular contexts, highlighting their complicated biological roles in different biological interactions. Ultimately the present survey tries to demonstrate the crucial roles of MPs in cancer cells and the different mechanisms that occur in the mentioned cells in order to emphasize performing more studies about clarifying the roles of MPs in carcinogenesis.

P3, N=61, Active, not recruiting, Alliance for Clinical Trials in Oncology | Trial completion date: Sep 2026 --> Sep 2027 | Trial primary completion date: May 2024 --> Mar 2026

P2, N=30, Recruiting, German Oncology Center, Cyprus

P2, N=716, Recruiting, Fudan University | Trial primary completion date: Sep 2024 --> Dec 2024

P2, N=379, Completed, Novartis Pharmaceuticals | Active, not recruiting --> Completed | Trial completion date: Jul 2025 --> Nov 2024

P4, N=62, Recruiting, Aristotle University Of Thessaloniki | Not yet recruiting --> Recruiting

P=N/A, N=349, Active, not recruiting, Peking University People's Hospital | Recruiting --> Active, not recruiting | N=240 --> 349

P3; Trial primary completion date: May 2028 --> Jun 2025

P=N/A, N=0, Withdrawn, Sir Mortimer B. Davis - Jewish General Hospital | N=65 --> 0 | Not yet recruiting --> Withdrawn

P2, N=130, Completed, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Active, not recruiting --> Completed | Trial completion date: May 2025 --> Dec 2024

P2/3, N=102, Active, not recruiting, Sir Mortimer B. Davis - Jewish General Hospital | Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2025 --> Apr 2027

P2, N=65, Active, not recruiting, Jules Bordet Institute | Trial completion date: Oct 2024 --> Jan 2025 | Trial primary completion date: Aug 2024 --> Jan 2025

Initially treated for early-stage disease with surgery, chemotherapy, radiotherapy, and ET, she progressed to metastatic disease and received ribociclib, letrozole, and goserelin, achieving a partial response. Managed with prednisolone and azathioprine, ribociclib was reintroduced at a reduced dose and later escalated to full dose. This case report highlights the importance of a multidisciplinary approach to balance oncologic efficacy with hepatologic safety.

P2, N=74, Not yet recruiting, University of Chicago | Initiation date: Jul 2024 --> Jan 2025

P=N/A, N=42, Completed, Medical College of Wisconsin | Active, not recruiting --> Completed

P=N/A, N=14, Recruiting, Fudan University | Not yet recruiting --> Recruiting

There are subgroups of patients, such as those with low baseline cancer burden and PTEN/ERG wild-type status, more likely to achieve good response with nADT. In the case of long term oncological benefit to be proven, nADT might be an additional therapeutic resource for these patients.

Methods Pre/perimenopausal pts with no prior systemic therapy for aggressive HR+/HER2− ABC were randomized 1:1 to RIB + letrozole/anastrozole + goserelin or physician's choice of combo CT. Contrary results in the CT arm suggest that these signatures warrant further studies on their potential predictive value. These data are hypothesis generating and should be interpreted with caution due to small sample sizes.